ZYBTNasdaqPharmaceutical Preparations
Zhengye Biotechnology Holding Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 28, 2026
$1.45+0.05 (+3.57%)
Close on Oct 19, 2026
Zhengye Biotechnology Holding Ltd income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- 20.5%
- Operating margin
- -60.6%
- Net margin
- -60.0%
- Return on equity, FY2025
- -26.1%
Financial strength
- Current ratio
- 1.14
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 41.8%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
Valuation ratios need the share price and fill in once daily prices are connected.